Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the sale, the chief executive officer now owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. This represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
Enliven Therapeutics Price Performance
Enliven Therapeutics stock opened at $20.89 on Thursday. Enliven Therapeutics, Inc. has a one year low of $15.96 and a one year high of $30.03. The company's fifty day moving average price is $21.39 and its two-hundred day moving average price is $23.78. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -10.99 and a beta of 1.04.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Institutional Trading of Enliven Therapeutics
Large investors have recently modified their holdings of the company. California State Teachers Retirement System increased its stake in shares of Enliven Therapeutics by 10.2% in the fourth quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after purchasing an additional 1,940 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Enliven Therapeutics by 67.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after acquiring an additional 17,546 shares in the last quarter. Stempoint Capital LP bought a new stake in Enliven Therapeutics in the fourth quarter valued at about $2,176,000. Polar Capital Holdings Plc grew its position in Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in shares of Enliven Therapeutics by 29.5% during the fourth quarter. ProShare Advisors LLC now owns 12,229 shares of the company's stock valued at $275,000 after acquiring an additional 2,788 shares during the period. 95.08% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, BTIG Research assumed coverage on Enliven Therapeutics in a research note on Friday, December 13th. They set a "buy" rating and a $42.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $38.25.
Check Out Our Latest Stock Analysis on Enliven Therapeutics
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
